Libtayo fda approval history last updated by judith stewart, bpharm on oct 9, 2025 In a significant step forward for skin cancer management, the u.s Yes (first approved september 28, 2018) brand name
Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation.
Last week, regeneron announced the u.s
